Your selections will be saved and used to recommend products based on your interests.
Nov 16 2014 9:00AM - Nov 18 2014 6:00PM | Tokyo Big Sight
Recent DIA activities have been developing cooperation between government, industry and academia to promote commercialization of innovative medical technologies and products in Japan, the US and Europe, and, with the participation of patients, worked toward dramatic progress in the development of new medical technologies, drugs and medical devices. These movements share the goal of clearly transcending a number of boundaries in order to achieve meaningful new medical innovations.In Japan, in order to promptly provide world-class medical technology to the public, a new act on Regenerative Medicine, the "Act Concerning Safety Assurance of Regenerative Medicine, etc." and revision of the Pharmaceutical Affairs Act to introduce an Accelerated Drug Approval Program with conditions and time limits according to the characteristics of regenerative and other medicines, were established on November 20.Coupled with this framework of new regulations, breakthrough discoveries and inventions originating from Japan, such as human induced pluripotent stem (iPS) cells and the medical robot suit, are expected to expand the horizons for health care of the future.There are a wide variety of boundaries that we must transcend including those between industry, academia, government and patients, between specialized fields within science and technology, between pharmaceutical drugs, medical devices, and regenerative medicine, and boundaries that separate countries and regions. If the development of pharmaceutical drugs and medical devices only follows traditional methodologies and the assumptions of our current development environment, it will become increasingly difficult to bring about revolutionary breakthroughs. It is now essential for open innovation to break down existing barriers. Our conference title this year calls on us to transcend these boundaries and even surpass what we have taken as common sense or expected practice up until now with a strong will to make changes that can create a revolution in medical care.The theme of the Japan Annual Meeting last year was "Revolutionary Drug Development." This year, we would like to help you work across disciplines and areas of expertise to create medical innovation beyond all boundaries for the realization of a revolution in medical care that truly meets the needs of patients.
Attendees should make airline and hotel reservations as early as possible. To reserve your room at the Sun Route Hotel Ariake or the Washington Hotel Tokyo Bay Ariake being located close to the venue, please contact below:
Hotel Sun Route AriakeAddress: 3-6-6 Ariake, Koto-ku, Tokyo 135-0063Telephone: +81-3-5530-3610URL: http://www.sunroute.jp/ariake/
Washington Hotel Tokyo Bay AriakeAddress: 3-7-11 Ariake, Koto-ku, Tokyo 135-0063Telephone: +81-3-5564-0111URL: http://tokyobay.washington-hotels.jp/
The most convenient airport is Haneda Airport and airport limousine bus services are available between the airport and the Tokyo Big Sight. For further information on the airport transportation, please visit the following link: http://www.limousinebus.co.jp/en/bus_services/haneda/odaiba_ariake.html
Please contact the DIA Japan office in Tokyo for further information.
Tel: +81-3-5575-2130Fax: +81-3-3583-1200DIAJapan@diajapan.org www.diajapan.org
Foundation for Biomedical Research and Innovation, Japan
General Manager, CDM and Biostatistics, Pharmaceutical Development DivisionNippon Kayaku Co., Ltd., Japan
Associate Director, Drug Fostering & Evolution Coordination Dept, CMA HQsEisai Co., Ltd., Japan
Director of Clinical Research CenterChiba University Hospital, Japan
Senior Manager, Policy Intelligence Dept.Janssen Pharmaceutical K.K., Japan
Sr Scientist, CMC Regulatory Affairs, Regulatory Affairs Area, Japan DevelopmentMSD K.K., Japan
Japan Development Leader, CV/MET, Clinical ResearchPfizer Japan Inc., Japan
ChairmanGENEX Partners, Japan
Labelling Department, Development and Medical Affairs DivisionGlaxoSmithKline K.K., Japan
Senior Director, Regulatory Affairs Group, Asia Development DeptDaiichi Sankyo Co., Ltd., Japan
Director, Asia Pacific Data Sciences & SolutionsEli Lilly Japan K.K., Japan
Head, Regulatory Operation & Prescribing Information Group, Drug RA Dept.Novartis Pharma K.K., Japan
Clinical Pharmacologist, Clinical Pharmacology, Clinical ResearchPfizer Japan Inc., Japan
Senior ManagerAstellas Pharma Inc., Japan
Manager, Quality Management, Quality & Regulatory Compliance Dept.Chugai Pharmaceutical Co., Ltd., Japan
Biostatistics Group, Data Science, Drug Development Div.Dainippon Sumitomo Pharma Co., Ltd., Japan
Review Director, Office of New Drug IIIPharmaceuticals and Medical Devices Agency (PMDA), Japan
Head, Department of BiostatisticsNational Cancer Center, Japan
MSD K.K., Japan
Director, Division of Regulatory Cooperation, Office of International ProgramsPharmaceuticals and Medical Devices Agency (PMDA), Japan
The 11th Annual Meeting DIA Japan 2014 offers interested companies following exhibit and support opportunities.
All prices include 8% Consumption Tax